본문 바로가기
KERD
논문KCI 등재

Correlation Between Testosterone Replacement Treatment and Lower Urinary Tract Symptoms

감성철|신유섭|이민호
대한배뇨장애요실금학회 (Korean Continence Society)|2021.11|International Neurourology Journal|제25권 제1호|pp. 12-22|DOI 10.5213/inj.2040234.117

1

조회

0

다운로드

2

인용

0

참고문헌

키워드

Lower urinary tract symptomsTestosteroneBenign prostatic hyperplasiaHypogonadismAndrogens

초록

Lower urinary tract symptoms (LUTS) are a cluster of voiding symptoms, such as weak stream, hesitancy, intermittency, urinary frequency, urgency, and nocturia. LUTS are frequent in elderly men and it considered the ultimate clinical symptoms of benign prostatic hyperplasia. With aging, male hypogonadism is increased which is defined as decreased ability of the testes to produce sperm and sex steroids because of a pituitary/hypothalamic, or testicular deficiency. In academic andrology associations, the term “male hypogonadism” is commonly used to categorize testosterone deficiency. Testosterone deficiency syndrome (TDS) is defined as a decrease in serum testosterone accompanied by symptoms such as libido decrease, depressive disorder, erectile dysfunction, and fatigue. Although the mechanism about testosterone-replacement therapy (TRT) effects on men with hypogonadism is not yet identified, TRT has been shown to effectively relieve the symptoms of TDS as well as LUTS by several studies. Although the present review demonstrates the effectiveness and safety of TRT in men with TDS by prior studies, future large scale of clinical trials should be conducted to present more high-quality evidence to clinicians and patients.

Abstract

Lower urinary tract symptoms (LUTS) are a cluster of voiding symptoms, such as weak stream, hesitancy, intermittency, urinary frequency, urgency, and nocturia. LUTS are frequent in elderly men and it considered the ultimate clinical symptoms of benign prostatic hyperplasia. With aging, male hypogonadism is increased which is defined as decreased ability of the testes to produce sperm and sex steroids because of a pituitary/hypothalamic, or testicular deficiency. In academic andrology associations, the term “male hypogonadism” is commonly used to categorize testosterone deficiency. Testosterone deficiency syndrome (TDS) is defined as a decrease in serum testosterone accompanied by symptoms such as libido decrease, depressive disorder, erectile dysfunction, and fatigue. Although the mechanism about testosterone-replacement therapy (TRT) effects on men with hypogonadism is not yet identified, TRT has been shown to effectively relieve the symptoms of TDS as well as LUTS by several studies. Although the present review demonstrates the effectiveness and safety of TRT in men with TDS by prior studies, future large scale of clinical trials should be conducted to present more high-quality evidence to clinicians and patients.

참고문헌 (94)

  1. 박정옥, "Sex Differences in Lower Urinary Tract Symptoms in Older Korean Adults Living in Rural Areas: Prevalence, Quality of Life, and Associated Factors", International Neurourology Journal, 22(3), pp.212~219 (2018), 대한배뇨장애요실금학회
  2. 고일규, "Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats", International Neurourology Journal, 22(1), pp.20~29 (2018), 대한배뇨장애요실금학회
  3. Abdulmaged M. Traish, "Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome", The World Journal of Men's Health, 36(3), pp.199~222 (2018), 대한남성과학회
  4. Schubert M, "Testosterone deficiency syndrome in the aging male (TDS): definition, diagnostic and clinical aspects", J Endocrinol Invest, 28, pp.23~27 (2005)
  5. Feldman HA, "Age trends in the level of serum testosterone and other hormones in middle-aged men : longitudinal results from the Massachusetts male aging study", J Clin Endocrinol Metab, 87, pp.589~598 (2002)
  6. Harman SM, "Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging", J Clin Endocrinol Metab, 86, pp.724~731 (2001)
  7. DeLay KJ, "Testosterone and the prostate : artifacts and truth", Urol Clin N Am, 43, pp.405~412 (2016)
  8. Araujo AB, "Prevalence of symptomatic androgen deficiency in men", J Clin Endocrinol Metab, 92, pp.4241~4247 (2007)
  9. Kupelian V, "Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample : the Boston Area Community Health(BACH)Survey", Arch Intern Med, 166, pp.2381~2387 (2014)
  10. Wang C, "Testosterone replacement therapy improves mood in hypogonadal men–a clinical research center study", J Clin Endocrinol Metab, 81, pp.3578~3583 (1996)
  11. Wang C, "Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men", J Clin Endocrinol Metab, 85, pp.2839~2853 (2000)
  12. Seidman SN, "Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression", J Affect Disord, 48, pp.157~161 (1998)
  13. Snyder PJ, "Effects of testosterone re-placement in hypogonadal men", J Clin Endocrinol Metab, 85, pp.2670~2677 (2000)
  14. Kenny AM, "Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty", J Am Geriatr Soc, 56, pp.1134~1143 (2010)
  15. Dobs AS, "Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypogonadal men", J Clin Endocrinol Metab, 84, pp.3469~3478 (1999)
  16. Giovanni Corona, "Risks and Benefits of Late Onset Hypogonadism Treatment: An Expert Opinion", The World Journal of Men's Health, 31(2), pp.103~125 (2013), 대한남성과학회
  17. Baillargeon J, "Trends in androgen prescribing in the United States, 2001 to 2011", JAMA Intern Med, 173, pp.2013~2014 (2014)
  18. Favilla V, "Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia", BJU Int, 106, pp.1700~1703 (2010)
  19. Litman HJ, "An investigation of the relationship between sex-steroid levels and urological symptoms : results from the Boston Area Community Health survey", BJU Int, 100, pp.321~326 (2007)
  20. Wang C, "Investigation, treatment, and monitoring of testosterone deficiency syndrome in males: ISA, ISSAM, EAU, EAA, and ASA recommendations", J Androl, 30, pp.1~9 (2009)
  21. Cui Y, "The effect of androgen-replacement therapy on prostate growth : a systematic review and meta-analysis", Eur Urol, 64, pp.811~822 (2013)
  22. Behre HM, "A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-oflife in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up", Aging Male, 15, pp.198~207 (2012)
  23. Marks LS, "Effect of testosterone replacement therapy on prostate tissue in men with testosterone deficiency syndrome : a randomized controlled trial", JAMA, 296, pp.2351~2361 (2006)
  24. Meuleman EJ, "Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism", Aging Male, 18, pp.157~163 (2015)
  25. Basaria S, "Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or lownormal testosterone levels : a randomized clinical trial", JAMA, 314, pp.570~581 (2015)
  26. Seftel AD, "Critical update of the 2010endocrine society clinical practice guidelines for male hypogonadism : a systematic analysis", Mayo Clin Proc, 90, pp.1104~1115 (2015)
  27. Corona G, "Update in testosterone therapy for men", J Sex Med, 8, pp.639~654 (2011)
  28. Corona G, "Emerging medication for the treatment of male hypogonadism", Expert Opin Emerg Drugs, 17, pp.239~259 (2012)
  29. Morgentaler A, "Shifting the paradigm of testosterone and prostate cancer : the saturation model and the limits of androgen-dependent growth", Eur Urol, 55, pp.310~320 (2009)
  30. Rastrelli G, "Serum PSA as a predictor of testosterone deficiency", J Sex Med, 10, pp.2518~2528 (2013)
  31. Schatzl G, "The Prostate Study Group of the Austrian Society of Urology", Urology, 55, pp.397~402 (2000)
  32. Schauer IG, "The functional role of reactive stroma in benign prostatic hyperplasia", Differentiation, 82, pp.200~210 (2011)
  33. Cunha GR, "Stromal-epithelial interactions, I: induction of prostatic phenotype in urothelium of testicular feminized mice", J Steroid Biochem, 14, pp.1317~1324 (1981)
  34. Vignera S, "Endocrine control of benign prostatic hyperplasia", Andrology, 4, pp.404~411 (2016)
  35. Timms BG, "Instructive induction of prostate growth and differentiation by a defined urogenital sinus mesenchyme", Microsc Res Tech, 30, pp.319~332 (1995)
  36. Donjacour AA, "Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgeninsensitive mice", Endocrinology, 132, pp.2342~2350 (1993)
  37. Roehrborn CG, "Pathology of benign prostatic hyperplasia", Int J Impot Res, 20(Suppl 3), pp.S11~S18 (2008)
  38. Nicholson TM, "Androgens and estrogens in benign prostatic hyperplasia: past, present and future", Differentiation, 82, pp.184~199 (2011)
  39. Vignozzi L, "Benign prostatic hyperplasia : a new metabolic disease", J Endocrinol Invest, 37, pp.313~322 (2014)
  40. Kellokumpu-Lehtinen P, "Correlation of early cytodifferentiation of the human fetal prostate and Leydig cells", Anat Rec, 196, pp.263~273 (1980)
  41. Cunha GR, "Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors", Andrology, 13, pp.465~475 (1992)
  42. Wu FC, "Hypothalamic-pituitarytesticular axis disruptions in older men are differentially linked to age and modifiable risk factors : the European Male Aging Study", Clin Endocrinol Metab, 93, pp.2737~2745 (2008)
  43. Corona G, "Androgen regulation of prostate cancer : where are we now", J Endocrinol Invest, 34, pp.232~243 (2011)
  44. Harman SM, "Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging", J Clin Endocrinol Metab, 86, pp.724~731 (2001)
  45. Lenzi A, "Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism", J Endocrinol Invest, 32, pp.934~938 (2009)
  46. Mulligan T, "Prevalence of hypogonadism in males aged at least 45 years : the HIM study", Int J Clin Pract, 60, pp.762~769 (2006)
  47. Shigehara K, "Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy : a randomised controlled study", Aging Male, 14, pp.53~58 (2011)
  48. Imperato-McGinley J, "Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency", Mol Cell Endocrinol, 198, pp.51~59 (2002)
  49. 최훈, "The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea", International Neurourology Journal, 20(4), pp.342~348 (2016), 대한배뇨장애요실금학회
  50. Barkin J, "Benign prostatic hyperplasia and lower urinary tract symptoms : evidence and approaches for best case management", Can J Urol (2011)
  51. Steiner GE, "Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue", Lab Invest, 83, pp.1131~1146 (2003)
  52. Macoska JA, "Chemokines and BPH", LUTS, 2011, pp.82, 253~260
  53. Lee JH, "Relationship between benign prostatic hyperplasia", lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men, 2014, pp.11, 1309~1315
  54. Steiner GE, "Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate", Prostate, 56, pp.171~182 (2003)
  55. Nickel JC, "The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis", Curr Opin Urol, 16, pp.5~10 (2006)
  56. Hung SC, "Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk", Br J Cancer, 108, pp.1778~1783 (2013)
  57. Condorelli RA, "Male accessory gland inflammation prevalence in type 2 diabetic patients with symptoms possibly reflecting autonomic neuropathy", Asian J Androl, 16, pp.761~766 (2014)
  58. Rastrelli G, "Testosterone and benign prostatic hyperplasia", Sex Med Rev, 7, pp.259~271 (2019)
  59. Mosli HH, "Metformin attenuates testosterone-induced prostatic hyperplasia in rats : a pharmacological perspective", Sci Rep, 5, pp.15639~ (2015)
  60. Murff HJ, "Thiazolidinedione and Metformin use and the risk of benign prostate hyperplasia in Veterans with diabetes mellitus", J Mens Health, 11, pp.157~162 (2014)
  61. Gacci M, "Metabolic syndrome and benign prostatic enlargement : a systematic review and metaanalysis", BJU Int, 115, pp.24~31 (2015)
  62. Lotti F, "Metabolic syndrome and prostate abnormalities in male subjects of infertile couples", Asian J Androl, 16, pp.295~ (2014)
  63. Schenk JM, "Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial", Am J Epidemiol, 171, pp.571~582 (2010)
  64. Gacci M, "Benign prostatic enlargement can be influenced by metabolic profile : results of a multicenter prospective study", BMC Urol, 17, pp.22~ (2017)
  65. Russo GI, "Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms(MIPS Study)", BJU Int, 121, pp.799~804 (2018)
  66. Corona G, "Clinical correlates of enlarged prostate size in subjects with sexual dysfunction", Asian J Androl, 16, pp.767~ (2014)
  67. Buvat J, "Testosterone deficiency in men : systematic review and standard operating procedures for diagnosis and treatment", J Sex Med, 10, pp.245~284 (2013)
  68. Petering RC, "Testosterone therapy : review of clinical applications", Nor Am Fam Phy, 96, pp.441~449 (2017)
  69. Wang C, "Investigation, treatment and monitoring of testosterone deficiency syndrome in males: ISA, ISSAM, EAU, EAA and ASA recommendations", Eur J Endocrinol, 159, pp.507~514 (2008)
  70. Mohr BA, "Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study", Clin Endocrinol, 62, pp.64~73 (2005)
  71. Wu FC, "Identification of testosterone deficiency syndrome in middle-aged and elderly men", N Engl J Med, 363, pp.123~135 (2010)
  72. Huggins C, "Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941", J Urol, 168, pp.9~12 (2002)
  73. Holmäng S, "Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men", Prostate, 23, pp.99~106 (1993)
  74. Morales A, "Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer : preliminary observations", BJU Int, 103, pp.62~64 (2009)
  75. Bhasin S, "Testosterone therapy in men with androgen deficiency syndromes : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 95, pp.2536~2559 (2010)
  76. (2020)[URL]
  77. Kazuyoshi Shigehara, "Testosterone Deficiency and Nocturia: A Review", The World Journal of Men's Health, 35(1), pp.14~21 (2017), 대한남성과학회
  78. Washino S, "Impact of androgen deprivation therapy on volume reduction and lower urinary tract symptoms in patients with prostate cancer", Low Urin Tract Symptoms, 10, pp.57~63 (2018)
  79. Liverman CT, "Testosterone and aging: clinical research directions" (2004), The National Academies Press
  80. Tek M, "The effect of testosterone replacement therapy for bladder functions and histology in orchiectomized mature male rats", Urology, 75, pp.886~890 (2010)
  81. Celayir S, "Effects of different sex hormones on male rabbit urodynamics : an experimental study", Horm Res, 60, pp.215~220 (2003)
  82. Yassin AA, "Lower urinary-tract symptoms and testosterone in elderly men", World J Urol, 26, pp.359~364 (2008)
  83. Wilt TJ, "Systematic review : comparative effectiveness and harms of treatments for clinically localized prostate cancer", Ann Intern Med, 148, pp.435~448 (2008)
  84. Bhasin S, "Age-associated sarcopenia–issues in the use of testosterone as an anabolic agent in older men", J Clin Endocrinol Metab, 82, pp.1659~1660 (1997)
  85. Badawi JK, "Is testosterone important in LUT function in men and women", Neurourol Urodyn, 36, pp.859~862 (2017)
  86. Walther HW, "Hormonal treatment of benign prostatic hyperplasia", J Urol, 40, pp.135~144 (1938)
  87. Pearl JA, "Testosterone supplementation does not worsen lower urinary tract symptoms", J Urol, 190, pp.1828~1833 (2013)
  88. Yassin DJ, "Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational, longitudinal registry study", World J Urol, 32, pp.1049~1054 (2014)
  89. Haider A, "Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalization of plasma testosterone levels in hypogonadal elderly men", Andrologia, 41, pp.7~13 (2009)
  90. Debruyne FMJ, "Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms : prostate health outcomes in the Registry of Hypogonadism in Men", BJU Int, 119, pp.216~224 (2017)
  91. Kohn TP, "Effects of testosterone replacement therapy for lower urinary tract symptoms : a systematic review and meta-analysis", Eur Urol, 69, pp.1083~1090 (2016)
  92. Karazindiyanoğlu S, "The effect of testosterone therapy on lower urinary tract symptoms", bladder and sexual functions in men with symptomatic testosterone deficiency syndrome, 2008, pp.11, 146~149
  93. Kalinchenko S, "Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism : a pilot study", Aging Male, 11, pp.57~61 (2008)
  94. 고영휘, "Testosterone Replacement Alone for Testosterone Deficiency Syndrome Improves Moderate Lower Urinary Tract Symptoms: One Year Follow-Up", The World Journal of Men's Health, 31(1), pp.47~52 (2013), 대한남성과학회

관련 논문AI추천

Nocturia is the Lower Urinary Tract Symptom With Greatest Impact on Quality of Life of Men From a Community SettingAriel Gustavo Scafuri, Bruno Roberto da Silva Ferreira, Cristiano Mendes Gomes, Eduardo de Paula Miranda, Fábio César Miranda Torricelli, Homero Bruschini, José de Bessa Júnior, José Everton de Castro, Miguel Srougi대한배뇨장애요실금학회 · International Neurourology Journal2014 · 제18권 제2호A Relationship of Sex Hormone Levels and Erectile Dysfunction: Which Tests Should Be Done Routinely?Bilal G？m？？, Co？kun B？y？ksu, G？khan Temelta？, Talha M？ezzino？lu, Zeki Arı연세대학교의과대학 · Yonsei Medical Journal2007 · 제48권 제6호하부요로증상/전립선비대증 일차 치료의 최근 경향정희창영남대학교 의과대학 · Journal of Yeungnam Medical Science2009 · 제26권 제2호Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects김계환, 김태범, 윤상진대한배뇨장애요실금학회 · International Neurourology Journal2010 · 제14권 제1호Lower Urinary Tract Symptoms and Erectile Dysfunction in Men With Type 2 Diabetes Mellitus강덕희, 강지영, 고관표, 김성대, 문성실, 송효정, 이대호, 이은주, 허정식, 홍성철, Nancy Bergstrom대한배뇨장애요실금학회 · International Neurourology Journal2013 · 제17권 제4호Comprehensive Review of COVID-19 on Benign Prostate Hyperplasia Patient Symptoms김정준, 서홍진, 이동환, 황태곤, Joongwon Choi대한요로생식기감염학회 · Urogenital Tract Infection2022 · 제17권 제2호

이 간행물의 다른 논문 (21건)

Strategies for Overcoming Intractable Disorders or Memory Impairments김창주pp. 1-2The Microbiome and Urology조영삼pp. 1-2The Urinary Tract Microbiome in Male Genitourinary Diseases: Focusing on Benign Prostate Hyperplasia and Lower Urinary Tract Symptoms김명수, 정승일pp. 3-11Current Pharmacologic Strategies for Treatment of Intractable Epilepsy in Children조경옥, 문자운pp. 8-18Polydeoxyribonucleotide Attenuates Airway Inflammation Through A2AR Signaling Pathway in PM10-Exposed Mice김수연, 최천웅, 조영아, 고일규, 진준장, 장복순, 황락경, 성준석pp. 19-26
원문 보기